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Abstract
Introduction: Dysregulation of the insulin-like growth factor-1 receptor (IGF-1R)/phosphatidylinositol-3-kinase
(PI3K)/Akt pathway was shown to correlate with breast cancer disease progression. Cancer stem cells are a
subpopulation within cancer cells that participate in tumor initiation, radio/chemoresistance and metastasis. In
breast cancer, breast cancer stem cells (BCSCs) were identified as CD24-CD44+ cells or cells with high intracellular
aldehyde dehydrogenase activity (ALDH+). Elucidation of the role of IGF-1R in BCSCs is crucial to the design of
breast cancer therapies targeting BCSCs.
Methods: IGF-1R expression in BCSCs and noncancer stem cells sorted from xenografts of human primary breast
cancers was examined by fluorescence-activated cell sorting (FACS), western blot analysis and immunoprecipitation.
The role of IGF-1R in BCSCs was assessed by IGF-1R blockade with chemical inhibitor and gene silencing.
Involvement of PI3K/Akt/mammalian target of rapamycin (mTOR) as the downstream pathway was studied by their
phosphorylation status upon IGF-1R inhibition and the effects of chemical inhibitors of these signaling molecules
on BCSCs. We also studied 16 clinical specimens of breast cancer for the expression of phosphor-Akt in the BCSCs
by FACS.
Results: Expression of phosphorylated IGF-1R was greater in BCSCs than in non-BCSCs from xenografts of human
breast cancer, which were supported by western blot and immunoprecipitation experiments. The sorted IGF-1R-
expressing cells displayed features of cancer stem/progenitors such as mammosphere formation in vitro and
tumorigenicity in vivo, both of which were suppressed by knockdown of IGF-1R. A specific inhibitor of the IGF-1R,
picropodophyllin suppressed phospho-AktSer473 and preferentially decreased ALDH+ BCSC populations of human
breast cancer cells. Furthermore, picropodophyllin inhibited the capacity of CD24-CD44+ BCSCs to undergo the
epithelial-mesenchymal transition process with downregulation of mesenchymal markers. Inhibitors of signal
molecules downstream of IGF-1R including PI3K/Akt/mTOR also reduced the ALDH+ population of breast cancer
cells. Furthermore, the mTOR inhibitor, rapamycin, suppressed BCSCs in vitro and in vivo.
Conclusion: Our data support the notion that IGF-1R is a marker of stemness, and IGF-1R and its downstream
PI3K/Akt/mTOR pathway are attractive targets for therapy directed against breast cancer stem/progenitors.
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Introduction
Cancers are well known to consist of heterogeneous popu-
lations of cells that differ in marker expression, prolifera-
tion capacity, and tumorigenicity [1,2]. The existence of
cancer stem cells (CSCs) has been reported in a variety of
malignancies, including leukemia [3], and solid tumors
such as brain cancer [4], breast cancer [5], and colon can-
cer [6]. In breast cancer, CD24-CD44+ [5] or cells with
high aldehyde dehydrogenase (ALDH) activity [7] have
been shown to be enriched in breast cancer stem cells
(BCSCs). In addition to their tumor-initiating capacity,
BCSCs were reported to be radiation resistant [8] and
prone to metastasis [9,10]. Eradication of BCSCs is thus a
key to curative therapy of breast cancer [11], and identify-
ing pathways crucial for BCSCs may provide valuable
clues for therapeutic targets.
The phosphatidylinositol-3-kinase (PI3K)/Akt (also
known as protein kinase B) pathway has been demon-
strated to be dysregulated in many types of cancer,
including breast cancer [12], and to be associated with
poor prognosis [13,14]. In tumors, hyperactivation of
the PI3K/Akt pathway may occur by activation of
upstream growth factor receptors, overexpression or
amplification of Akt, or inactivation of a phosphatase
and tensin homolog tumor suppressor [15]. One of the
growth receptors associated with activation of Akt is
insulin-like growth factor-1 receptor (IGF-1R), which
can turn on the signaling cascade of the PI3K/Akt/
mammalian target of rapamycin (mTOR) pathway upon
stimulation with insulin-like growth factor-1 (IGF-1)
[16]. The expression of IGF-1 in breast cancer tissues
[17] and serum of breast cancer patients [18] was signif-
icantly higher than those in normal healthy individuals.
Besides, overexpression and hyperphosphorylation of the
IGF-1R in primary breast tumors were reported to cor-
relate with radioresistance and tumor recurrence [19].
Although the IGF-1/IGF-1R pathway seems to be
important in breast cancer, its role in BCSCs remains to
be delineated. In this study, we investigated the possibi-
lity that IGF-1R signal might play an important role in
the tumorigenicity and maintenance of BCSCs.
Methods
Ethics statement
All of the studies involving human participates were fully
encoded to protect patient confidentiality and were uti-
lized under a protocol approved by the Institutional
Review Board of Human Subjects Research Ethics Com-
mittees of Tri-Service General Hospital and by Academia
Sinica, Taipei, Taiwan. All patients enrolled in this study
have signed an informed consent form to agree to partici-
pate in this study and for publication of the results.
All of the animal studies were operated following a
protocol approved by the Institutional Animal Care &
Utilization Committee of Academia Sinica, Taipei,
Taiwan.
Isolation and transplantation of primary tumor cells
Primary breast cancer cells were harvested from tumor
tissues as described previously [20]. All human breast
cancer specimens were obtained from patients who had
undergone initial surgery at the Tri-Service General
Hospital (Taipei, Taiwan). Samples were fully encoded
to protect patient confidentiality and were utilized
under a protocol approved by the Institutional Review
Board of Human Subjects Research Ethics Committees
of Tri-Service General Hospital and Academia Sinica,
Taipei, Taiwan.
After receiving the specimens, tumor mass was sliced
into 1 mm pieces and digested with collagenase/hyalur-
ondiase digestion buffer (StemCell Technologies, Van-
couver, BC, Canada) at 37°C for 2 hours. The released
tumor cells were collected after filtration with a 40 μm
cell strainer (BD Biosciences, San Jose, CA, USA). Before
inoculation of primary tumor cells, 8-week-old female
NOD/SCID mice (Tzu Chi University, Hualien, Taiwan)
received a sublethal dose of gamma irradiation. For
initial establishment and serial passages of xenografts,
1×106 tumor cells were mixed with 5×105 normal
human breast fibroblasts/site in 2 mg/ml Matrigel and
were subcutaneously injected into mammary fat pads of
mice. For CSC frequency determination, a serial dilution
of sorted tumor cells was mixed with normal human
breast fibroblasts and Matrigel and was injected into
mammary fat pads of NOD/SCID mice as described
above. The tumor formation was monitored weekly.
CSC frequency was calculated by Extreme Limiting
Dilution Analysis software [21].
Fluorescence-activated cell sorting
Anti-CD24-PE, anti-CD44-APC, anti-H2Kd-FITC, and
anti-IGF-1R-PE antibody were purchased form BD Bios-
ciences and the ALDEFLUOR assay kit was purchased
from StemCell Technologies. Cell labeling with fluores-
cent-conjugated antibodies or ALDEFLUOR assay was
performed according to the manufacturer’s recommen-
dations. Sorting of antibody-labeled cells was carried out
on a FACSAria cell sorter (BD Biosciences).
Cell culture and reagents
Sorted H2Kd-CD24-CD44+ cells from BC0145 xenograft
and H2Kd-ALDH+ cells from BC0244 xenograft were cul-
tured in MEM containing 10% fetal bovine serum and
insulin (10 μg/ml) at 37°C with 5% CO2 and designated
AS-B145 and AS-B244, respectively. They could be propa-
gated in serial passages, with emergence of phenotypic
diversity of ALDH activity as noted in xenografted tumors.
These cultured cells served as convenient in vitro cell
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models for investigating the signaling pathways involved in
the maintenance of BCSCs. CB-124005 (Akt inhibitor), PI-
103 (PI3K/mTOR inhibitor), rapamycin (mTOR inhibitor),
and picropodophyllin (PPP; IGF-1R inhibitor) were pur-
chased from Calbiochem (Billerica, MA, USA), and FPA-
124 (Akt inhibitor) was purchased from Tocris Bioscience
(Bristol, BS, UK). All of the small-molecule inhibitors were
dissolved in dimethylsulfoxide.
Knockdown of IGF-1R expression
Negative control siRNA or IGF-1R-specific siRNA were
purchased from Santa Cruz Biotechnology (Dallas, TX,
USA) and delivered into cells by Metafectene SI transfec-
tion reagent (Biontex Laboratories GmbH, Martinsried,
Germany) at 100 nM according to the manufacturer’s pro-
tocol. For in vivo xenograftment assay, knockdown of IGF-
1R was performed by lentivirus-mediated gene silencing.
The lentivirus that carry luciferase-specific shRNA (sh-Luc)
or IGF-1R-specific shRNA (sh-IGF-1R) were obtained from
the National RNAi Core Facility at the Institute of Molecu-
lar Biology, (Academia Sinica, Taipei, Taiwan), produced
and transduced into cells as described previously [20].
Fluorescence-activated cell sorting analysis of pAktSer473
and E-cadherin
Tumor cells from primary breast tumor tissue were
resuspended in staining buffer (0.2% BSA in PBS con-
taining 0.05% NaN3) containing an antibody against
phosphor-Akt (Ser473; BD Biosciences), anti-CD45-
PerCP-Cy5.5, anti-CD24-PE, and anti-CD44-APC. Phos-
phor-AktSer473-expressing cells in BCSCs (CD45-/CD24-/
CD44+) and non-BCSCs (other cells in the CD45- popu-
lation) were further analyzed with FACSCalibur (BD
Biosciences) flow cytometer and WinMDI software (The
Scripps Research Institute, La Jolla, CA, USA). For
determination of E-cadherin expression by fluorescence-
activated cell sorting (FACS), cells were harvested by
5 mM ethylenediamine tetraacetic acid treatment, incu-
bated with mouse monoclonal anti-E-cadherin antibody
(Santa Cruz Biotechnology), followed by Alexa-488 con-
jugated secondary antibody (Molecular Probes, Grand
Island, NY, USA).
Mammosphere formation assay
Cells were resuspended in Dulbecco’s MEM-F12 medium
containing 1% methyl cellulose to avoid cell aggregation,
and basic fibroblast growth factor (20 ng/ml; PeproTech,
Rocky Hill, NJ, USA), human epidermal growth factor
(20 ng/ml; PeproTech), insulin (5 μg/ml), and B27 supple-
ment (at a 50× dilution; GIBCO, Grand Island, NY, USA).
Cells were seeded at 1,000 cells/well into ultralow-attach-
ment 96-well plates (Corning Life Sciences, Tewksbury,
MA, USA). After 7 days of incubation, the number of
mammospheres was counted using bright-field optical
microscopy under a 20× objective lens, and data were pre-
sented as the sphere number per 1,000 cells.
Western blot analysis
Cells were lysed in RIPA lysis buffer containing NP-40.
Twenty-five micrograms of extracted protein was sepa-
rated using a 4 to 12% gradient NuPAGE (Invitrogen,
Grand Island, NY, USA) and transferred to a polyvinyli-
dene difluoride membrane (Immobilon-P; Millipore, Bill-
erica, MA, USA). The membrane was then incubated with
antibodies against Akt, phosphor-Akt (Ser473), mTOR,
phosphor-mTOR (Ser2448), GAPDH (Cell Signaling
Technology, Danvers, MA, USA), phospho-insulin recep-
tor (Tyr972), insulin receptor (IR; GeneTex Inc., Irvine,
CA, USA) phospho-IGF-1R (Tyr1165/1166; Santa Cruz
Biotechnology), b-actin (Sigma-Aldrich, St. Louis, MO,
USA), and the IGF-1R (R&D Systems, Minneapolis, MN,
USA). Alkaline phosphatase-conjugated anti-rabbit or
anti-mouse immunoglobulin G (Promega, Madison, WI,
USA) was used as the secondary antibody. Fluorescent sig-
nals from catalyzed ECF substrate were scanned using a
Typhoon9400 Variable Mode Imager (Amersham
BioScience, Pittsburgh, PA, USA). The quantifications of
band intensities were calculated with ImageJ software
(National Institutes of Health, Bethesda, MD, USA) or
Bio1D (Vilber Lourmat, Marne-la-Vallée, France).
p-IGF-1RTyr1165/1166 analysis after immunoprecipitation of
IGF-1Rb
Total cell lysates (500 μg) from sorted ALDH- or ALDH
+ BC0244 xenograft tumor cells were used for immuno-
precipitation analysis. Briefly, 1 μg IGF-1Rb specific
antibody (sc-713; Santa Cruz Biotechnology) was added
into cell lysates (500 μg/200 μl Tris-buffered saline) and
incubated at 4°C overnight. After adding 10 μl Protein
G Mag Sepharose beads (GE Healthcare Life Science,
Pittsburgh, PA, USA), the solutions were further incu-
bated for 2 hours at room temperature. The beads were
then proper washed and the binding proteins were
eluted by 1× SDS-PAGE sample loading dye. The eluted
proteins were further separated by 10% SDS-PAGE and
blotted with anti-p-IGF-1RTyr1165/1166 and anti-IGF-1Rb
antibodies according the protocol of western blot
analysis.
Cell migration assay
Cells were suspended in serum-free culture medium,
seeded at in the upper chamber insert of a transwell plate
(Corning Life Sciences) and then inserted into 24-well
plates with serum-containing medium. After incubation at
37°C for 16 hours, cells that had migrated across the
membrane of the insert were stained with crystal violet
after removing the cells attached on the inner face of the
insert and results were recorded by microscopy.
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Immunofluorescence staining of E-cadherin
Cells were fixed with cold methanol followed by 3.7%
formaldehyde/PBS. After blocking with 1% BSA/PBS,
cells were incubated with an anti-E-cadherin antibody
and then further incubated with an Alexa-488-conju-
gated secondary antibody. Fluorescence signals were
captured under an inverted fluorescence microscope
(Olympus, Shinjuku-ku, Tokyo, Japan).
Results
Increased IGF-1R activity in BCSCs of xenograft of human
breast cancer
Xenografts of two human breast cancers, BC0145 and
BC0244, were established by inoculating primary human
breast cancer cells in the mammary fat pads of NOD/
SCID mice. BC0145 tumor was estrogen receptor (ER)-
negative, progesterone receptor (PR)-positive, HER2/neu-
positive, and BC0244 was triple negative. The engrafted
tumors displayed similar histology and expression status
of ER/PR/Her2 as the patients’ specimens [20] (see Figure
S1 in Additional file 1). To determine the BCSC popula-
tion in BC0145 and BC0244 xenografts, CD24-CD44+ and
ALDH+ cells were sorted from H2Kd- cells using FACS
(see Figure S2 in Additional file 1) and injected into the
mammary fat pads of NOD/SCID mice. The xenograft-
ment results indicated that CSCs could be enriched in
H2Kd-CD24-CD44+ or H2Kd-ALDH+ cells because of their
higher tumorigenicity (see Table S1 in Additional file 1)
and in vivo re-emergence of heterogeneity as their parental
tumors (see Figure S2D for CD24-CD44+ and Figure S2G,
H for ALDH+ in Additional file 1). These two xenografted
human breast cancers are suitable for investigating the
characteristics of BCSCs.
We next compared the activation status of the IGF-1R
in BCSCs and non-BCSCs sorted from BC0145 and
BC0244 xenografts by western blot. The amount of the
phosphorylated IGF-1RTyr1165/1166 was greater by 1.10-fold
to 2.32-fold in CD24-CD44+ and ALDH+ BCSCs than
non-CD24-CD44+ and ALDH- cells in both xenografts
(Figure 1A). The total IGF-1R in the BCSC-enriched
population was also 1.23-fold to 5.19-fold that of non-
BCSCs. We further performed chromatin immunoprecipi-
tation analysis to support the western blot results of
p-IGF-1RTyr1165/1166 because of the cross-reactivity
between p-IGF-1R and phosphorylated IR. After immuno-
precipitation with IGF-1Rb-specific antibody, p-IGF-
1RTyr1165/1166 was also increased 1.64-fold in ALDH+
BC0244 xenograft tumor cells when compared with
ALDH- cells (Figure 1B). In line with these findings,
the levels of IGF1R mRNAs were also increased in
CD24-CD44+ BC0145 and ALDH+ BC0244 BCSCs (see
Figure S3A in Additional file 1). To distinguish the possi-
ble involvement of IR, we also examined the expression of
IR and phosphorylated IR in BCSCs and non-BCSCs.
Unexpectedly, the IR expression as well as its phosphoryla-
tion in BCSCs of BC0145 xenograft cells was markedly
lower than those in non-BCSCs, but there was no obvious
difference between BCSCs and non-BCSCs of BC0244
xenograft cells (see Figure S3B in Additional file 1). These
findings suggest that IGF-1R, but not IR, is activated to a
greater extent in BCSCs than non-BCSCs and that IGF-1R
signaling may play a crucial role in BCSCs.
IGF-1R serves as a novel marker for breast cancer stem/
progenitors
Given the importance of IGF-1R signaling in the progres-
sion of breast cancer, we next examined whether IGF-1R
could serve as a marker for BCSCs. FACS analysis of
BC0145 revealed that 91.2% and 48.0% of IGF1R+ cells
were CD24-CD44+, and ALDH+, respectively, as compared
with 3.3% and 17.2% of IGF1R- cells bearing these mar-
kers, respectively (Figure 1C, upper panel). As for BC0244
xenograft tumor cells, 83.8% and 54% of IGF1Rhi were
CD24–CD44+and ALDH+, respectively, as compared with
48.7% and 31.9% of IGF-1Rlo cells, respectively (Figure 1C,
lower panel). These results indicated that IGF-1Rhi breast
cancer cells were enriched for CSC markers. We next
used western blot to confirm the expression of IGF-1R in
IGF-1R+/IGF-1Rhi cells and the results showed greater
expression of total IGF-1R protein level in sorted IGF-1R
+/IGF-1Rhi cells (2.66-fold or 1.25-fold in IGF-1R+ BC0145
cells or IGF-1Rhi BC0244 cells, respectively) as well as
total P-IGF-1R (2.05-fold or 1.24-fold in IGF-1R+ BC0145
cells or IGF-1Rhi BC0244 cells, respectively), although the
ratio of P-IGF-1R/IGF-1R was less in IGF-1R+ BC0145
cells (see Figure S3C in Additional file 1).
To confirm whether IGF-1R could serve as a marker
for BCSCs, BC0145 or BC0244 xenograft tumor cells
were sorted into IGF-1R+/IGF-1R- (BC0145) or IGF-
1Rhi/IGF-1Rlo cells (BC0244), respectively (the purity of
FACS are shown in Figure S3D in Additional file 1), and
tested for tumorigenicity in vitro and in vivo. As
expected, IGF-1R+ BC0145 or IGF-1Rhi BC0244 cells
displayed greater capacity of mammosphere formation,
with increased size (Figure 1D) and number (Figure 2A)
of spheres. In vivo, IGF-1R+ BC0145 and IGF-1Rhi
BC0244 cells displayed greater tumorigenicity in NOD/
SCID mice than IGF-1R- BC0145 and IGF-1Rlo BC0244
cells (Figure 1E). For BC0145, the CSC frequency of
IGF-1R+ cells was higher than IGF-1R- cells, which
failed to generate any tumor with up to 105 cells (P =
0.0036). Similar results were observed in BC0244 (P =
8.94×10-78). In addition, tumor cells derived from IGF-
1R+ BC0145 cells or IGF-1Rhi BC0244 cells displayed
phenotypic diversity in IGF-1R expression as the original
tumor (see Figure S4A in Additional file 1). Further ana-
lysis of these tumors showed that more than 90% of
IGF-1Rhi cells were CD24-CD44+ but less than 30% of
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IGF-1R-/lo were CD24-CD44+ (see Figure S4B in Addi-
tional file 1), indicating the capacity of IGF-1R+/IGF-
1Rhi cells to undergo differentiation when they formed
tumors in vivo.
IGF-1R blockade abolishes the cancer stem/progenitor
features in vitro and in vivo
To further support the use of IGR-1R as a marker for
breast cancer stem/progenitors, the effects of IGF-1R
inhibition on the CSC features were determined. Upon
treatment with picropodophyllin (PPP), a specific small-
molecule inhibitor of the IGF-1R that has no effects on
the related receptor tyrosine kinases such as insulin
receptor [22] and epidermal growth factor receptor [23],
the mammosphere forming capacity of IGF-1R+ BC0145
and IGF-1Rhi BC0244 cells was significantly reduced
(Figure 2A).
To facilitate further studies of the role of IGF-1R, we
established cultured cell lines derived from H2Kd-CD24-
CD44+ and H2Kd-ALDH+ cells of xenografts of BC0145
and BC0244, respectively. These cells could be propa-
gated in serial passages with emergence of phenotypic
Figure 1 Insulin-like growth factor 1 receptor serves as a marker for breast cancer stem cells. (A) Cells from xenograft BC0145 or BC0244
tumors were sorted as indicated populations and phosphorylation of insulin-like growth factor 1 receptor (IGF-1R) was determined by western
blot. (B) pIGF-1RTyr1165/1166 of immunoprecipitated IGF-1R from aldehyde dehydrogenase (ALDH)- or ALDH+ BC0244 xenograft tumor cells was
determined. (C) Tumor cells of BC0145 or BC0244 xenografts were stained with PE-conjugated anti-IGF-1R antibody and FITC-conjugated anti-
H2Kd antibody. CD24-CD44+ or ALDH+ cells within IGF-1R+/IGF-1R- BC0145 cells (upper panel in (B)) or IGF-1Rhi/IGF-1Rlo BC0244 cells (lower panel
in (B)) were determined by co-stain with PE-Cy7-conjugated anti-CD24/APC-conjugated anti-CD44 antibodies or Aldefluor substrate. (D), (E) Two
populations of IGF-1R+/IGF-1R- (BC0145) or IGF-1Rhi/IGF-1Rlo (BC0244) cells were sorted from the H2Kd- population by fluorescence-activated cell
sorting (FACS) and determined the mammosphere formation capability (D) or tumorigenicity (E). The CSC frequency was calculated by ELDA
software (table in (E)). All experiments were repeated independently at least twice and results shown were from a representative experiment. IP,
immunoprecipitation; IB, immunoblot.
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Figure 2 Disruption of insulin-like growth factor 1 receptor activity diminished the breast cancer stem cell population. (A) Two
populations of insulin-like growth factor 1 receptor (IGF-1R)+/IGF-1R- (BC0145) or IGF-1Rhi/IGF-1Rlo (BC0244) cells were sorted as described in
Figure 1B and the mammosphere formation capability determined in the presence of 0.1% dimethylsulfoxide (DMSO) or 1 μM picropodophyllin
(PPP). *P <0.05; #P <0.01. (B) The mammosphere forming capability of AS-B145 or AS-B244 cells under PPP or 0.1% DMSO treatment was
determined. *P <0.05; #P <0.01. (C) Cells were transfected with 100 nM of negative control siRNA (ctrl siRNA) or IGF-1R specific siRNA (IGF-1R KD)
and cells were harvested to determine the mammosphere forming capability. *P <0.05; #P <0.01. (D) IGF-1R+ BC0145 or IGF-1Rhi BC0244 cells
were sorted, transduced with sh-Luc or sh-IGF-1R lentivirus and the tumorigenicity determined in NOD/SCID mice. All experiments were
repeated independently at least twice and results shown were from a representative experiment. ALDH, aldehyde dehydrogenase.
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diversity of ALDH activity as noted in parental tumors.
These cultured cells derived from BCSCs of BC0145
and BC0244 were designated AS-B145 and AS-B244,
respectively, and served as convenient in vitro cell mod-
els for investigating the signaling pathways involved in
the maintenance of BCSCs. Incubation of AS-B145
and AS-B244 cells with PPP for 48 hours resulted in a
dose-dependent decrease in their ALDH+ population
(Figure 2B). Furthermore, silencing of IGF-1R in AS-
B145 cells inhibited the total number of mammospheres
to 80.5 ± 2.6% of the control siRNA (P = 0.012) and
64.4 ± 4.4% (P = 0.021) for those spheres >100 μm. The
suppressive effect was even more pronounced for AS-
B244 cells, down to 25.9 ± 6.2% (P = 0.007) and 4.3 ±
2.0% (P = 0.004) for the total number of mammosphere
and larger spheres, respectively (Figure 2C).
We next determined whether knockdown of IGF-1R
suppresses the tumorigenicity of IGF-1R expressing
breast cancer stem/progenitors. Lentivirus-mediated
silencing of IGF-1R in IGF-1R+ BC0145 or IGF-1Rhi
BC0244 cells suppressed their tumorigenicity in NOD/
SCID mice, with tumor formation in only one out of
four mice by week 9 after injection of sh-IGF-1R trans-
duced IGF-1R+ BC0145 cells, and no tumor formation
up to week 15 after injection of sh-IGF-1R transduced
IGF-1Rhi BC0244 cells. In contrast, tumor formation
was noted in three of four mice at week 9 or three of
three mice by week 15 after injection of sh-Luc trans-
duced IGF-1R+ BC0145 or IGF-1Rhi BC0244 cells,
respectively (Figure 2D; see also Figure S4C in Addi-
tional file 1). Interestingly, the percentage of IGF-1R+
cells (4.3%) in the single tumor derived from the sh-
IGF-1R group was significantly less than that from the
sh-Luc group (35.2%), whereas the percentage of CD24-
CD44+ cells was similar between the two groups (34.9%
and 37.2% in the sh-IGF-1R group and sh-Luc group,
respectively) (see Figure S4D in Additional file 1). Taken
together, IGF-1R inhibition not only decreased the CSC
population of breast cancer but also suppressed the
mammosphere formation and tumor growth of IGF-1R+
cells. These results lent further support that IGF-1R
could serve as a novel marker for breast cancer stem/
progenitors and that IGF-1R signaling was crucial in the
maintenance of this particular population within breast
cancer.
In view of the reported involvement of IGF-1R signal-
ing in the metastasis [24,25] and epithelial-mesenchymal
transition (EMT) [26] of breast cancer cells, we further
investigated whether IGF-1R signal also regulates EMT
process in CD44+ BCSCs. Incubation of sorted CD44+
AS-B244 cells with PPP suppressed the migration ability
of BCSCs in a transwell assay in a dose-dependent man-
ner, with negligible migration at 5 μM (Figure 3A). This
was accompanied by a concentration-dependent change
of cell morphology from mesenchymal appearance to
cuboidal shape (Figure 3A, bright field), although some
morphological heterogeneity was noted in CD44+
AS-B244 cells without PPP treatment. Repression of E-
cadherin, a hallmark of EMT, was also examined by
immunofluorescence staining, which revealed a progres-
sive increase in E-cadherin expression in CD44+ AS-
B244 cells incubated with increasing concentrations of
PPP (Figure 3A; see also Figure S4E in Additional file 1).
Upregulation of E-cadherin by PPP was also confirmed
by FACS analysis, with an increase in the percentage and
mean fluorescence intensity of E-cadherin-positive cells
of sorted CD44+ AS-B244 cells upon treatment with PPP
(see Figure S4F in Additional file 1). Analysis of other
EMT markers by western blot revealed that PPP treat-
ment led to concentration-dependent decreases in the
expression of vimentin, N-cadherin, and twist, but not
snail (Figure 3B). These results indicate that IGF-1R sig-
naling is required not only for the survival of BCSCs, but
also for their capability to undergo EMT.
IGF-1R signaling leads to Akt activation in BCSCs
To examine whether IGF-1R is a possible upstream sti-
mulus of the PI3K/Akt/mTOR pathway in BCSCs, we
first tested the activation status of Akt/mTOR between
BCSCs and non-BCSCs. The phosphorylation of AktSer473
(pAktSer473) and mTORSer2448 (p-mTORSer2448) was
higher in CD24-CD44+ and ALDH+ BCSCs; and an
increased amount of Akt and mTOR proteins was also
noted in ALDH+ BC0145 cells, CD24-CD44+ BC0244
cells, and ALDH+ BC0244 cells (Figure 3C). The
increased protein level of Akt or mTOR was accompa-
nied by the upregulation of their mRNA (see Figure S4 in
Additional file 1). We next tested whether disruption of
the IGF-1R signaling will reduce Akt activation. Knock-
down of IGF-1R decreased the phosphorylation of Akt-
Ser473 in both AS-B145 and AS-B244 cells (Figure 3D).
Similar results were observed in PPP-treated ALDH+ AS-
B145 and ALDH+ AS-B244 cells in a dose-dependent
manner at 18 hours (Figure 3E). We further examined
the effects of disruption of the PI3K/Akt/mTOR pathway
in the CSC population of breast cancer cells. AS-B145
and AS-B244 cells were incubated with a PI3K/mTOR
inhibitor (PI-103), Akt specific inhibitors (CB-124005
and FPA-124), or rapamycin for 48 hours, and the num-
ber of viable BCSC population identified as ALDH+ 7-
AAD- cells was determined by FACS analysis. The
percentages of ALDH+ cells in both AS-B145 (Figure 4A)
and AS-B244 cells (Figure 4B) diminished upon treat-
ment with PI-103, CB-124005, FPA-124, and rapamycin
in dose-dependent manners, with more pronounced
inhibition by PI-103 and rapamycin. This was accompa-
nied by a decrease in AktSer473 phosphorylation after
treatment with PI-103, CB-124005, and FPA-124,
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Figure 3 Targeting IGF-1R affects cancer stem cell properties and Akt activation of breast cancer stem cells. (A) CD44+ cells of AS-B244
cells were treated with picropodophyllin (PPP) for 12 hours and cell migration within 18 hours was determined (upper panel). E-cadherin
expression was determined by immunofluorescence stain (middle panel, 10× objective lens). Cell morphology was observed under microscope
(bright field, 20× objective lens). (B) The expression of epithelial-mesenchymal transition-related molecules after PPP treatment was determined
by western blot. (C) Cells were sorted as described in Figure 1A and the phosphorylation of Akt or mammalian target of rapamycin (mTOR) was
determined by western blot. GAPDH and actin were used as internal control for BC0145 and for BC0244, respectively. (D) AS-B145 or AS-B244
cells were transfected with 100 nM negative control siRNA (ctrl) or insulin-like growth factor 1 receptor (IGF-1R) specific siRNA (KD) for 48 hours
and the expression of IGF-1R, Akt or p-Akt was determined by western blot. (E) ALDH+ AS-B145 or ALDH+ AS-B244 cells were treated with PPP
for 48 hours. pAktser473was determined by western blot. All experiments were repeated at least twice and results shown were from a
representative experiment. ALDH, aldehyde dehydrogenase; DMSO, dimethylsulfoxide.
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although the phosphorylation of mTOR, the downstream
signal molecule of Akt, was suppressed only by PI-103
(Figure 4C).
We next examined whether rapamycin could inhibit
the self-renewal of BCSCs in vitro. The mammosphere
formation capacity of BC0145 xenograft tumor was
inhibited by rapamycin in a concentration-dependent
manner at 25 to100 nM (Figure 5A). The survival
BCSCs were also much more susceptible than non-
BCSCs to the inhibitory effects of rapamycin, with IC50
of 10.4 ± 1.4 nM and 320.6 ± 99.4 nM for BCSCs and
non-BCSCs, respectively (Figure 5B). Furthermore, treat-
ment of NOD/SCID mice with rapamycin for 3 weeks
suppressed the in vivo tumorigenicity of BCSCs by more
than 99% of the vehicle control (Figure 5C). In order to
investigate whether rapamycin treatment reduces prolif-
eration of BCSCs in vivo, we inoculated 105 CD24-CD44
+ cells sorted from BC0145 xenograft. Two weeks later,
mice were treated with rapamycin for 3 weeks and the
resulting tumors were measured and harvested for
assessment of BCSC activity by mammosphere forma-
tion assay. As shown in Figure 5D,E, rapamycin inhib-
ited tumorigenicity of BCSCs as reflected by reduced
tumor volume to 23.5 ± 7.7% of vehicle control (P =
0.008) and mammosphere forming capacity of H2Kd-
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Figure 4 Targeting the PI3K/Akt/mTOR pathway inhibits the cancer stem cell population of breast cancer cells. (A) AS-B145 cells or (B)
AS-B244 cells were treated with small molecule inhibitors of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) (PI-103),
Akt (CB-124005 or FPA-124) or mTOR (rapamycin) for 48 hours and the aldehyde dehydrogenase (ALDH)+ cell population within 7-
aminoactinomycin D (7-AAD)-negative cells was determined with Aldefluor assay and displayed as the relative percentage of dimethylsulfoxide
(DMSO) control. *P <0.05; #P <0.01 when compared with the DMSO group. (C) pAktser473 or p-mTORSer2448 was determined with western blot
after treatment with inhibitors for 18 hours. Data are presented as the fold of changes relative to the DMSO control. All experiments were
repeated independently at least twice and results shown were collected from a representative experiment.
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Figure 5 Rapamycin suppresses stem cell population, in vitro cell proliferation and in vivo tumorigenicity. (A) CD24-CD44+ cells of BC0145
xenograft tumors were cultured for mammosphere formation for 7 days, and the number of spheres were counted and shown as the number per
1,000 cells. #P <0.01. (B) Differential sensitivity of breast cancer stem cells (BCSCs) and non-BCSCs to rapamycin in vitro. BCSCs and non-BCSCs were
cultured at 1×104 cells/well with rapamycin and cell titers were determined at 48 hours by alamar blue assay. (C) Effects of rapamycin on
tumorigenicity of BCSCs in vivo. Groups of three NOD/SCID mice were inoculated with 105 cells of BCSCs in the mammary fat pads and treated
with intraperitoneal injections of rapamycin every 2 days at 4 mg/kg for 3 weeks. Tumor volumes were monitored weekly from weeks 4 to 9. #P
<0.01. (D) The CD24-CD44+ BC0145 cells were injected into mammary fat pads. Two weeks later, the mice were treated with rapamycin at 2 mg/
kg/every 2 days for first week and 1 mg/kg/every 2 days for a further 2 weeks. The therapeutic effect of rapamycin was demonstrated by the
reduced tumor formation and tumor volume. The BCSC activity in vehicle-treated or rapamycin-treated tumors was determined by mammosphere
forming capability. To avoid the influence of mouse cells, the assay was conducted with H2Kd- tumor cells. #P <0.01. All experiments were repeated
independently at least twice and results shown were collected from a representative experiment. CSC, cancer stem cell; DMSO, dimethylsulfoxide.
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These findings were in sharp contrast to the increased
proportion of BCSCs and enhanced mammosphere
forming capacity observed after treatment with doxoru-
bicin [27] or taxol [28], lending further support that
rapamycin could suppress the survival of BCSCs. These
results indicate that the efficient suppression of the
PI3K/mTOR pathway by small-molecule inhibitors pre-
ferentially purges the BCSC population.
We next examined the activation status of Akt in 16 pri-
mary breast cancer specimens. The clinical and histo-
pathological characteristics of these 16 breast cancer
patients are summarized in Table S2 of Additional file 1.
Freshly harvested tumor cells with CD45-CD24-CD44+
marker were delineated as BCSCs, with the remaining
CD45- population as non-BCSCs, and their expression of
intracellular pAktSer473 was determined by FACS (see
Figure S4A in Additional file 1 for an illustrated an exam-
ple of BC0417). Among 16 primary human breast cancer
specimens, pAktSer473 was detected in 11 samples that dis-
played a significantly higher percentage of pAktSer473-posi-
tive cells in the BCSC population (ranging from 23.3 to
57.8%) than non-BCSCs (0 to 56.2%) (P = 0.048) (Table 1).
Among these 11 samples with positive pAktser473, the
expression levels of pAktser473 were higher in BCSCs than
non-BCSCs in seven samples, equivalent in two samples,
and lower in BCSCs in the remaining two samples (Table
1). There was no obvious correlation between the Akt acti-
vation in these 16 patients and their clinical stage (P =
0.11) or status of estrogen receptor, progesterone receptor
or HER2/neu (P = 0.59, 0.83 and 0.30, respectively) (see
Table S3in Additional file 1). Combining our previous
data [20], we investigated whether there was any correla-
tion between CD24-CD44+ percentage and breast cancer
subtypes, according to their expression profiles of ER, PR
and HER2/neu [29,30]. Among luminal A (ER/PR+,
HER2/neu-), luminal B (ER/PR+, HER2/neu+), HER2 over-
expression (ER-, PR-, HER2/neu+) and triple negative sub-
types of breast cancer, the CD24-CD44+ percentage was
only significantly increased in triple negative breast cancer
when compared with luminal B (P = 0.0464; see Figure
S5B in Additional file 1). Overall, these findings revealed
that Akt activation was greater in BCSCs than in non-
BCSCs for those samples with detectable p-Akt.
IGF-1R participates in the maintenance of BCSCs and Akt
activation in ER-positive breast cancer
The IGF-1R/ insulin receptor substrate-1 pathway is
reported to be activated greatly in ER-positive breast
cancer cells and contributes to their proliferation and
survival. We therefore investigated whether IGF-1R sig-
naling also controls the self-renewal capacity of ER-posi-
tive breast cancer cells. Treatment of two ER-positive
MCF7 and BT474 breast cancer cell lines with 5 μM
PPP significantly inhibited phosphorylation of Akt.
Their mammosphere forming capacities were also signif-
icantly suppressed by 0.2, 1 or 5 μM PPP in a concen-
tration-dependent manner (Figure 6A). In addition,
knockdown of IGF-1R by siRNA also reduced phos-
phorylated Akt and inhibited mammosphere formation
to 27.8 ± 2.4% or 20.5 ± 2.6% of negative control siRNA
in BT474 or MCF7 cells, respectively (Figure 6B). These
results indicated that the IGF-1R signaling pathway also
plays an important role in the maintenance of BCSCs in
both ER-positive and ER-negative breast cancers.
Discussion
In this study, we used the reported BCSC markers,
CD44/CD24, and ALDH activity to examine the role of
IGF-1R in BCSCs. We showed greater phosphorylation
of IGF-1R in BCSCs than in non-BCSCs and preferential
Table 1 Phosphorylated AktSer473 expression between BCSCs and non-BCSCs from primary human breast cancer
specimens
Expression level of p-AktSer473 (%, MFI)a
BCSCs (CD45-CD24-CD44+) Non-BCSCs (other populations of CD45- cells) Ratiob (BCSCs/non-BCSCs)
BC0414 33.3 (9.7) 17.5 (9.4) 1.90
BC0417 41.8 (32.0) 29.0 (33.0) 1.44
BC0422 32.4 (16.9) 14.3 (25.2) 2.27
BC0426 23.3 (5.2) 22.6 (5.7) 1.03
BC0450 41.3 (10.3) 56.2 (13.9) 0.73
BC0466 56.7 (36.5) 40.8 (44.1) 1.39
BC0480 55.7 (11.8) 37.8 (9.6) 1.47
BC0485 33.0 (44.2) 43.4 (54.8) 0.76
BC0512 57.8 (66.7) 37.8 (38.2) 1.53
BC0526 53.9 (28.2) 50.8 (34.4) 1.06
BC0533 47.8 (33.8) 0 ∞
BSCS, breast cancer stem cell; MFI, mean fluorescence intensity ap-AktSer473 expression was determined by flow cytometry as described in Materials and methods.
bThe ratio was calculated according to the positive percentage of pAktSer473 in BCSCs and non-BCSCs.
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Figure 6 IGF-1R is essential for the maintenance and Akt activation of estrogen receptor-positive breast cancer cells. (A) MCF7 or
BT474 breast cancer cells were treated with picropodophyllin (PPP) and harvested to detect Akt phosphorylation with western blot (right panel)
or mammosphere formation capability (left panel). Numbers in the left panel indicated relative expression in comparison with dimethylsulfoxide
(DMSO)-treated cells. Data of mammosphere formation assay presented as the relative percentage of DMSO-treated cells. *P <0.05; #P <0.01. (B)
MCF7 or BT474 cells were transfected with negative control siRNA (Ctrl-siRNA) or insulin-like growth factor 1 receptor (IGF-1R) specific siRNA [53]
for 48 hours and cells were harvested for detection of Akt phosphorylation by western blot (left panel) or mammosphere formation capability.
Data presented as relative percentage of Ctrl-siRNA transfected cells. *P <0.05; #P <0.01. All experiments were repeated independently at least
twice and results shown were collected from a representative experiment.
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sensitivity of BCSCs to PPP, a specific inhibitor of the
IGF-1R, leading to reduced phosphorylation of AktSer473
and decreased ALDH+ BCSC populations. In human
malignancies, increased circulating IGF-1 was associated
with a greater risk of several cancers, including breast
cancer [18]. A crosstalk between IGF-1R and the Wnt
pathway has been reported in colon cancer [31], oligo-
dendroglial cells [32], and chondrocytes [33]. The inter-
action of these two pathways in breast cancer is
intriguing and awaits further investigation. Recently, two
reports demonstrated the essential role of IGF/IGF-1R
signaling in the maintenance of leukemia-initiating cells
in T-cell acute lymphoblastic leukemia [34] or in the
transformation of hematopoietic progenitor cells in the
mouse model of acute myelogenous leukemia [35]. The
IGF-1R expression of leukemia-initiating cells in T-cell
acute lymphoblastic leukemia was maintained by Notch
signaling [34], which also contributed to the mainte-
nance of BCSCs [36,37]. Whether the Notch pathway is
involved in the IGF-1R signaling in BCSCs remains to
be investigated. In solid tumors, chemoresistant colorec-
tal cells displayed a CSC phenotype and became more
sensitive to IGF-1R inhibition [38]. In hepatocellular
carcinoma, the IGF-2/IGF-1R signal was shown to be
involved in Nanog-mediated self-renewal of hepatic
CSCs [39]. These reports also support the importance of
IGF-1R in CSC biology. In breast cancer, activation of
the IGF-1R could result in stimulation of proliferation
and metastasis through activation of insulin receptor
substrate-1 [40] and insulin receptor substrate-2 [41].
Furthermore, it has been reported that IGF-1R expres-
sion was positively correlated with a shorter disease-free
survival in triple negative breast cancer [42], the particu-
lar subtype with the highest rate of recurrence and
higher percentage of BCSCs than other breast cancer
subtypes [43]. In a recent report by Jones and collea-
gues, recurrence of breast cancer was observed in 16%
of inducible IGF-1R transgenic mice upon the disconti-
nuation of doxycycline and the recurrence involved IGF-
1R-reactivation and IGF-1R-independent mechanisms
[44]. Although the IGF-1R-independent tumors dis-
played EMT phenotypes, their metastatic potential was
much lower than tumors with IGF-1R reactivation [44].
Moreover, induction of EMT in immortalized human
mammary epithelial cells by overexpressing EMT-related
transcriptional factors, twist or snail, or treatment with
transforming growth factor b1 generated CD44+ BCSCs
[10]. Recently, Lorenzatti and colleagues found that
CCN6, a tumor inhibitory protein, could suppress the
expression of EMT transcriptional factor ZEB1 in breast
cancer cells through attenuation of IGF-1R signaling
[26]. Along this line, we also showed that inhibition of
IGF-1R signaling suppressed the cell migration ability of
CD44+ BCSCs through induction of E-cadherin, the
adhesion molecule that blocks the EMT process, as well
as suppression of other mesenchymal markers (vimentin,
twist and N-cadherin). More importantly, IGF-1R could
serve as a novel marker for a particular population of
cancer cells with stem/progenitor features within breast
cancer since IGF-1R high-expressing human breast can-
cer cells displayed the capacity for mammosphere for-
mation in vitro and tumorigenicity in vivo. Furthermore,
mammosphere formation of IGF-1R expressing BCSCs
was sensitive to PPP treatment. When comparing the
CSC frequency of different populations of breast cancer
cells, high expression of IGF-1R seems to be most effi-
cient in enriching BCSCs in a triple negative breast can-
cer BC0244 xenograft (one out of 909 cells; Figure 1D).
For BC0145 xenograft, the identification of cancer stem/
progenitors based on IGF-1R expression (one out of
54,785; Figure 1D) was slightly better than ALDH+ (one
out of 93,412; see Table S1 in Additional file 1) but not
as good as CD24-CD44+ (one out of 6,401; see Table S1
in Additional file 1). These results are consistent with
the known heterogeneity in the BCSC-enriched popula-
tion. It has been shown that overexpression of IGF-1R
in MCF7 increased the size of colonies under three-
dimensional culture conditions [45], which corroborated
our observation. To the best of our knowledge, this is
the first demonstration of IGF-1R as a marker for can-
cer stem/progenitors in breast cancer.
To further investigate the downstream signaling of IGF-
1R, we explored the involvement of the PI3K/Akt/mTOR
pathway. The upstream stimuli of the PI3K/Akt/mTOR
pathway in mammary stem/progenitor cells have been
linked to Wnt/b-catenin signaling. Korkaya and colleagues
demonstrated that phosphatase and tensin homolog
knockdown increased phosphorylation of Akt, leading to
enriched normal and malignant mammary stem/progeni-
tor cells, and that this Akt-driven process was mediated by
the Wnt/b-catenin pathway [46]. They also demonstrated
that perifosine, an Akt inhibitor, could suppress both in
vivo tumorigenicity and the in vitro ALDH+ population of
a breast cancer cell line and two xenografts of primary
breast cancer [46]. In this study, we documented enhanced
activation of PI3K/Akt/mTOR in BCSCs of primary
human breast cancer and two xenografts of primary
tumors, and suppressive effects of the mTOR inhibitor,
rapamycin, on their growth in vitro and in vivo, as well as
mammosphere formation. Herein, we have provided evi-
dence for another mechanism of activation of the PI3K/
Akt/mTOR pathway via IGF-1R signaling in BCSCs. The
importance of PI3K/Akt/mTOR in BCSCs of clinical sam-
ples is consistent with findings from previously reported
studies of breast cancer cell lines [46,47]. Enhanced phos-
phorylation of AktSer473 as determined by immunohisto-
chemical staining was reported to correlate with a poor
prognosis for breast cancer [14]. In the present study, it
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was demonstrated for the first time that pAktSer473 was
higher in CD45-CD24-CD44+ BCSCs than the non-
BCSCs, in a majority (7/11, 63.6%) of those primary
tumors with detectable pAkt and their xenografts in mice.
There was no obvious correlation with clinical and histo-
pathological features (see Table S2 in Additional file 1).
Although BCSCs are frequently enriched in CD24-CD44+
cells, such markers cannot be generalized to all patients,
given the inherent heterogeneity of breast cancer. The var-
iation of markers useful for enrichment of BCSCs among
patients may thus explain the lack of consistent elevation
of pAktSer473 in CD24-CD44+ cells in some patients.
Taken together, our findings support the notion that
IGF-1R signaling with activation of the downstream PI3K/
Akt/mTOR pathway plays an important role in breast can-
cer progression by controlling both the maintenance of
BCSCs and their EMT behavior. These studies also pro-
vide an impetus for developing cancer therapy targeting
BCSCs by combining inhibitors or mAb against IGF-1R
with inhibitors of the PI3K/Akt/mTOR pathway. Although
preclinical evidence for the efficacy of several small mole-
cule inhibitors and monoclonal anti-IGF-1R antibodies
(figitumumab, robatumumab and R1507) was strong,
large-scale clinical trials were halted due to very modest
activity [48]. The failure may be attributed in part to the
selection of appropriate target population, and in part to
the increased dependency of cancer cells on insulin [49].
Along this line, targeting IGF-1R and IR simultaneously
with OSI-906 and BMS 754807, which are small molecule
inhibitors of tyrosine kinase activity of both IGF-1R and
IR, is undergoing clinical trials [48]. In addition, recent
preclinical studies have shown that dual inhibition of
mTOR with rapamycin and Akt with perifosine prevents
mTOR inhibition-initiated Akt activation and significantly
enhances antitumor effects in lung cancer [50] and multi-
ple myeloma [51]. Also, combination of IGF-1R and
mTOR inhibition showed clinical benefits in Ewing’s sar-
coma [52]. With a similar strategy, dalotuzumab will be
combined with Akt or mTORC1 inhibition [48]. Thus, co-
targeting the PI3K/Akt/mTOR pathway and its upstream
signal, IGF-1R may prove to have synergistic anti-tumor
effects and is worthy of further investigation.
Conclusion
A new paradigm is emerging in cancer therapy by tar-
geting CSCs. In this study, we demonstrated that IGF-
1R could serve as a novel marker for a particular stem/
progenitor population within breast cancer and its sig-
naling pathway is critical for the survival and mainte-
nance of BCSCs. IGF-1R silencing or small molecule
inhibitors of IGF-1R and its downstream components
diminished the mammosphere forming capacity and in
vivo tumorigenicity of BCSCs. Analysis of clinical
specimens of breast cancer revealed significant upregula-
tion of phosphorylated Akt in BCSCs, which further
supported the importance of this pathway. Our findings
suggest that IGF-1R and its signaling via PI3K/Akt/
mTOR pathway are attractive targets for therapy direc-
ted against breast cancer stem/progenitors.
Additional material
Additional file 1: Supporting information. Supporting information
includes the methods of quantitative RT-PCR and the comparisons of
histology/markers between original patient’s tumor sections and
xenograft tumor sections of BC0244. It also includes the validation data
of BCSC characteristics of two xenograft breast cancer cells or IGF-1R+
sorted breast cancer cells. The clinical-histopathological characteristics of
breast cancer patients enrolled for detection of pAktser473 were also
included here.
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